Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Epizyme, Inc.
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Ipsen to acquire Epizyme, expanding its portfolio in oncology
June 27, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
IPSEY
OTC
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting
June 02, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme To Participate in H.C. Wainwright Global Investment Conference
May 17, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Date of First Quarter 2022 Financial Results
May 03, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update
March 15, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results
February 22, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Pricing of Public Offering of Common Stock
January 27, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Proposed Public Offering of Common Stock
January 26, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates
January 10, 2022
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting
December 12, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting
December 11, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting
December 02, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Updates to Its Board of Directors
November 18, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme to Participate in Jefferies London Healthcare Conference
November 12, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update
November 09, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414
November 04, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Date of Third Quarter 2021 Financial Results
November 02, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making
November 01, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress
September 14, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 20, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Announces CEO Succession
August 09, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update
August 09, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
August 08, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
HCM
Epizyme Announces Date of Second Quarter 2021 Financial Results
August 03, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients
June 16, 2021
From
Epizyme, Inc.
Via
Business Wire
Tickers
EPZM
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.